.png){kind=icon}
.png){kind=icon}
Return
Itolizumab targets the CD6-ALCAM axis to limit T-cell responses and brain barrier diapedesis in multiple sclerosis
.png){kind=icon}
PRE
AI
C
P
D
C
M
G
B
H
H
T
M
B
N
DOI：10.1016/j.jaut.2026.103598.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• CD6 expression pattern in MS enables selective targeting of pathogenic memory cells. • CD6 blockade mainly restrains inflammatory CD4+ T-cells diapedesis across the BBB. • CD6 blockade stabilizes BBB endothelial architecture and junctional protein levels. • CD6 blockade inhibits activation and tissue-residency programs in CD4+ T cells. • CD6 blockade potentially shields oligodendrocytes from direct T-cell injury.
Journal
IF:
7
Papers:
3.1K
Citations:
1.0W
Organization
Cited Papers